MedTrace Logo

Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects

NCT00605852 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2017-08-21

No results posted yet for this study

Summary

This study is designed to assess the safety and tolerability of single, escalating oral doses and repeat oral doses (7 days, once daily) of GSK835726 in healthy male subjects

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

DRUG

GSK835726

GSK835726 will be available in single dose and repeat dose formulations.

DRUG

Placebo

Placebo will be given to subjects.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-29
Primary Completion
2008-05-03
Completion
2008-05-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00605852 on ClinicalTrials.gov